GSK share price: why I think the world still needs GlaxoSmithKline for Covid-19

Jay Yao writes how GlaxoSmithKline could play more of a leading role against Covid-19 in the future, and what he thinks it means for the GSK share price.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE:GSK) share price hasn’t done much over the past year. As of the middle of February, the GSK share price has declined 3% in the last 12 months.

One reason for the GSK share performance could be that the company isn’t among the current leaders in Covid-19 vaccines. GSK’s Covid-19 vaccine candidate, which it worked on in conjunction with Sanofi, didn’t produce the initial results that it expected in the over-60 population. As a result, GSK might not have a vaccine ready until late this year or later.

While the result isn’t ideal, I nevertheless think GSK could have an opportunity to contribute to the fight. Here’s more and how I reckon the GSK share price could be affected as a result.

Why the world still needs GlaxoSmithKline

Although there are multiple vaccines for Covid-19 on the market already, I reckon the world will still need GlaxoSmithKline. I think this could affect the GSK share price as well.

First, demand for Covid-19 vaccines is so great that there will likely still be a need for Covid-19 vaccines against the initial strain in a year. If GlaxoSmithKline and Sanofi’s Covid-19 vaccine candidate is approved by regulators at that time, it could still be in demand.

Second, I don’t think it’s possible to fully end the coronavirus in a short amount of time given the limitations of current technology. Some think Covid-19 variants could be with us forever, which might make it necessary to have new vaccines every so often.

GlaxoSmithKline is the largest vaccine company by revenue, with leading research and development facilities, and immense manufacturing resources. If GSK’s leading R&D (either by itself or through collaboration) succeeds in developing a successful vaccine against a future variant quickly, the company could once again be among the leaders in the fight and realise more sales.

Given the company’s manufacturing capacity, GlaxoSmithKline could also be fighting against Covid-19 given its collaboration with German mRNA vaccine company CureVac (assuming that CureVac’s vaccine candidate gets approval).

Vaccines and the GSK share price

I reckon the GSK share price depends in part on how well its vaccines succeed, because vaccines are a huge business for GSK. In pre-pandemic 2019, GSK’s vaccine business generated £7.2bn in sales and accounted for around 21% of the company’s total sales of £33.8bn. GSK’s vaccine division was also growing quickly before the pandemic. In 2018, the division grew 16% year over year at constant exchange rates. In 2019, the vaccine division grew an even faster 19% year over year at constant exchange rates. Athough GlaxoSmithKline’s vaccine division sales were slightly lower due to the pandemic, I think it has a promising future given that much of the demand comes from emerging markets that will very likely grow in terms of income.

GSK’s vaccine division, along with the company’s potential to benefit from tech advances are two reasons I’d buy and hold GSK shares.

With this said, I’m mindful that the share performance could be disappointing if management doesn’t deliver the results that markets expect. Meaningful research and development is difficult and expensive, and doesn’t always produce results. Also, competition from generic products can hurt GSK’s profit margins.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jay Yao has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Up 125% in 5 years, the BAE share price has beaten Rolls-Royce. Which is better?

Both the BAE and Rolls-Royce share prices have been having a storming time. Here's how they stack up against each…

Read more »

Investing Articles

With P/E ratios of 7.2 and 9, I think these FTSE 100 shares are bargains!

The FTSE 100 has risen sharply in 2024, but there are still lots of top value shares out there. Royston…

Read more »

Investing Articles

This skyrocketing US growth stock has put all others to shame — including its core investment!

Up 378% this year, the spectacular growth of this US tech stock is leaving all others in the dust. But…

Read more »

Investing Articles

I’d buy this FTSE dividend share to target a lifelong second income

Our writer thinks investing in dividend stocks from the UK stock market is the best way for him to generate…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing For Beginners

The Barclays share price keeps surging! Was I wrong to sell the stock?

Jon Smith explains why the Barclays share price is still rising, even though he feels that further gains could be…

Read more »

Investing Articles

1 stock set to gatecrash the FTSE 100 in 2025!

Our writer considers a quality stock that's poised to join the FTSE 100 next year. Could there also be a…

Read more »

Businesswoman calculating finances in an office
Investing Articles

As earnings growth boosts the Imperial Brands share price, is it a top FTSE 100 dividend choice?

The Imperial Brands share price has come storming back as investors piled in for the big dividends. What's next, after…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

Warren Buffett just bought and sold these stocks. Here’s why I don’t agree

Jon Smith takes a look at the recent regulatory filing for Berkshire Hathaway and Warren Buffett and comments on recent…

Read more »